Louisiana to receive $6M in EpiPen settlement
BATON ROUGE- Louisiana has joined a multi-state settlement with Mylan Inc. that resolves allegations the drug manufacturer knowingly overcharged taxpayers for EpiPen and EpiPen Jr. dispensed to Medicaid beneficiaries.
The announcement came from Attorney General Jeff Landry’s office.
Mylan will pay $465 million to the federal government and the states, Louisiana’s portion is $6,922,152.05. Landry said the money will go towards replenishing the state’s Medicaid program.
Mylan allegedly submitted false statements to the Centers for Medicare and Medicaid Services that incorrectly classified EpiPen as a “non-innovator multiple source” drug, as opposed to a “single source” or “innovator multiple source” drug from July 29, 2010 to March 31 of this year.
As a result, Mylan submitted or caused false statements to be submitted to CMS and/or the states relating to EpiPen for Medicaid rebate purposes and underpaid its EpiPen rebates to the state Medicaid programs.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
President Trump leaves White House, makes final remarks to nation
Spring semester begins at Southern University
What to expect on Inauguration Day
An Inauguration Day unlike any other unfolds amid the COVID-19 pandemic
LDH calls for retired medical professionals to volunteer for vaccine administration